Liquidia Corp files patent infringement suit against United Therapeutics

Liquidia Corporation (NASDAQ:LQDA), a $1.13 billion market cap pharmaceutical company based in North Carolina, has initiated a patent infringement lawsuit against United Therapeutics (NASDAQ:UTHR) Corporation, according to a recent SEC filing. InvestingPro data shows the company maintains strong liquidity with current assets exceeding short-term obligations by over 4 times. The action, filed on Monday, April 21, 2025, in the United States District Court for the Middle District of North Carolina, alleges that United Therapeutics infringed on U.S. Patent No. 10,898,494. The patent in question pertains to a dry powder formulation of treprostinil, a drug used for the treatment of pulmonary hypertension.

The patent infringement filing represents a significant legal move by Liquidia Technologies, Inc., which is a wholly-owned subsidiary of Liquidia Corporation. The company has taken steps to protect its intellectual property rights surrounding its pharmaceutical preparations.

The details of the lawsuit, including the specific claims of infringement and the remedies sought by Liquidia, were not disclosed in the SEC filing. The outcome of this legal action could have implications for both companies involved. While analysts remain optimistic, with price targets ranging from $20 to $35, the potential impact on their operations and financial positions remains to be seen. Get deeper insights into Liquidia’s financial health and growth prospects with a comprehensive Pro Research Report, available exclusively on InvestingPro.

Investors and market watchers will likely follow the proceedings closely, as patent litigation can have material effects on pharmaceutical companies, especially when it involves drugs with significant market potential like treatments for pulmonary hypertension.

This lawsuit comes at a time when patent disputes are becoming increasingly common in the pharmaceutical industry, as companies seek to defend their research and development investments and maintain competitive advantages in the market. Investors should note that Liquidia is scheduled to report its next earnings on May 8, 2025, with analysts forecasting significant revenue growth of 186% for the current fiscal year.

The information reported is based on a press release statement filed with the SEC and does not include any speculative insights or predictions on the lawsuit’s outcome or broader industry impacts.

In other recent news, Liquidia Corporation reported its financial results for the fourth quarter of 2024, revealing a net loss and revenue shortfall compared to analyst forecasts. The company posted a Q4 2024 earnings per share (EPS) of -$0.45, missing the forecast of -$0.3821, and revenue for the quarter was $2.92 million, falling short of the $4.54 million forecast. Despite these figures, Liquidia remains optimistic about its future, particularly with the potential launch of its key product, Yutrepia, in May 2025. The U.S. Food and Drug Administration (FDA) has accepted Liquidia’s New Drug Application resubmission for Yutrepia, setting a Prescription Drug User Fee Act (PDUFA) goal date of May 24, 2025, for a final decision. Scotiabank (TSX:BNS) has raised Liquidia’s stock target to $34, citing positive expectations for Yutrepia’s commercial launch. Meanwhile, H.C. Wainwright maintains a Buy rating on Liquidia with a $29 target, focusing on the company’s progress with Yutrepia. Raymond (NSE:RYMD) James also reaffirmed a Strong Buy rating with a $27 target, based on the anticipated launch of Yutrepia around May 23, 2025. These developments highlight Liquidia’s strategic and financial initiatives as it navigates the regulatory landscape for Yutrepia’s approval and market entry.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.